SynthesisEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2026
Multiple Endocrine Neoplasia Type 5 due to Germline MAX Mutations: A Systematic Review of Tumor Spectrum and Clinical Features.
Synthesis in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The germline landscape of pituitary adenomas: established and emerging predisposition genes.The Journal of clinical endocrinology and metabolism · 2026Review
- Review
- Multiple endocrine neoplasia type 5: emerging evidence and clinical perspectives.Endocrine-related cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveWe aimed to summarize the tumor spectrum and clinical features of multiple endocrine neoplasia type 5 (MEN5) caused by heterozygous inactivating germline MYC-associated factor X (MAX) mutations.
methodsArticles were retrieved from PubMed and EMBASE from inception to June 2025 using search terms related to "MAX gene" and "MEN5". Additional cases were identified from a targeted Google Scholar search and supporting references of MAX variants reported in the ClinVar database. Eligible articles included those reporting patient-level data on individuals with germline MAX mutations. Data from all reported patients were extracted to generate a dataset containing phenotype information for descriptive analysis.
resultsOf 621 records screened, 45 studies comprising 127 patients with germline MAX mutations met the eligibility criteria. The median age at first tumor diagnosis was 29 years (23.0 - 39.0) and 37.0% were women. The most frequent tumors were pheochromocytoma (PCC, N = 112), pituitary adenoma (N = 11), and paraganglioma (N = 10), with median ages at diagnosis of 31.0, 33.0, and 43.0 years, respectively. Evidence implicating MAX loss in tumorigenesis included paraganglioma, pituitary adenoma, ganglioneuroma, neuroblastoma, pancreatic neuroendocrine tumor, renal oncocytoma, myelolipoma, and liver sarcoma. The causal association between primary hyperparathyroidism and MAX loss remains uncertain. Among PCCs, 38.3% were unilateral, 27.6% were metastatic, and most were norepinephrine-secreting.
conclusionOur systematic review characterized the tumor spectrum and clinical features of MEN5. While these findings outline the emerging clinical phenotype, further studies are needed to define the epidemiology, penetrance and genotype-phenotype associations of this newly recognized entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.